1. Home
  2. MIN vs RIGL Comparison

MIN vs RIGL Comparison

Compare MIN & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MIN
  • RIGL
  • Stock Information
  • Founded
  • MIN 1988
  • RIGL 1996
  • Country
  • MIN United States
  • RIGL United States
  • Employees
  • MIN N/A
  • RIGL N/A
  • Industry
  • MIN Trusts Except Educational Religious and Charitable
  • RIGL Biotechnology: Pharmaceutical Preparations
  • Sector
  • MIN Finance
  • RIGL Health Care
  • Exchange
  • MIN Nasdaq
  • RIGL Nasdaq
  • Market Cap
  • MIN 306.1M
  • RIGL 366.5M
  • IPO Year
  • MIN N/A
  • RIGL 2000
  • Fundamental
  • Price
  • MIN $2.72
  • RIGL $17.15
  • Analyst Decision
  • MIN
  • RIGL Buy
  • Analyst Count
  • MIN 0
  • RIGL 5
  • Target Price
  • MIN N/A
  • RIGL $36.80
  • AVG Volume (30 Days)
  • MIN 331.0K
  • RIGL 253.6K
  • Earning Date
  • MIN 01-01-0001
  • RIGL 03-04-2025
  • Dividend Yield
  • MIN 7.31%
  • RIGL N/A
  • EPS Growth
  • MIN N/A
  • RIGL N/A
  • EPS
  • MIN 0.08
  • RIGL 0.99
  • Revenue
  • MIN N/A
  • RIGL $179,278,000.00
  • Revenue This Year
  • MIN N/A
  • RIGL $14.19
  • Revenue Next Year
  • MIN N/A
  • RIGL $13.10
  • P/E Ratio
  • MIN $33.38
  • RIGL $17.17
  • Revenue Growth
  • MIN N/A
  • RIGL 54.71
  • 52 Week Low
  • MIN $2.52
  • RIGL $7.48
  • 52 Week High
  • MIN $2.88
  • RIGL $29.82
  • Technical
  • Relative Strength Index (RSI)
  • MIN 56.97
  • RIGL 32.74
  • Support Level
  • MIN $2.66
  • RIGL $19.81
  • Resistance Level
  • MIN $2.73
  • RIGL $19.97
  • Average True Range (ATR)
  • MIN 0.03
  • RIGL 1.04
  • MACD
  • MIN 0.00
  • RIGL -0.31
  • Stochastic Oscillator
  • MIN 83.33
  • RIGL 5.83

About MIN MFS Intermediate Income Trust

MFS Intermediate Income Trust is a diversified closed-end management investment company. The fund's investment objective is to seek high current income but may also consider capital appreciation. It invests the assets in debt instruments. Its portfolio of investments comprises of different sector investments such as the automotive, chemicals, energy, food and beverages, insurance, and other sectors.

About RIGL Rigel Pharmaceuticals Inc.

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Share on Social Networks: